SPDR Pharmac

UBS Upgrades Jazz Pharma to Buy, Raises Price Target to $307

FDA Accepts Viatris Meloxicam NDA, PDUFA Date Set for Dec 2026

LifeSci Capital Analyst Patrick Dolezal Maintains Buy Rating on MBX Biosciences with $91 Target Price

Liquidia Director Stephen M. Bloch Sells 319,000 shares of Common Stock

MBX Biosciences shares fall but analysts raise price targets

Axsome Therapeutics Receives FDA Approval for AUVELITY

Liquidia Tech released FY2026 Q1 earnings on May 11 Pre-Market (EST), actual revenue USD 132.87 M (forecast USD 119.4 M), actual EPS USD 0.5199 (forecast USD 0.41)

Mizuho Raises Axsome Therapeutics Price Target to $310

Esperion Therapeutics released FY2026 Q1 earnings on May 8 Pre-Market (EST), actual revenue USD 80.1 M (forecast USD 84.52 M), actual EPS USD -0.1002 (forecast USD -0.03)

MBX Biosciences released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5099 (forecast USD -0.5847)

Enliven Therapeutics released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.38 (forecast USD -0.4516)

Viatris released FY2026 Q1 earnings on May 7 During-Market (EST), actual revenue USD 3.517 B (forecast USD 3.357 B), actual EPS USD 0.15 (forecast USD -0.8445)

Viatris Q1 2026 Revenue and Earnings Per Share Exceed Expectations

Viatris Reports Q1 2026 Earnings and Reiterates Full-Year Guidance

Oppenheimer Increases Holdings in Axsome Therapeutics

Axsome Therapeutics COO sells 4,750 shares after exercising stock options

Trevi Therapeutics released FY2026 Q1 earnings on May 5 After-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.0906 (forecast USD -0.0722)

Jazz Pharma released FY2026 Q1 earnings on May 5 After-Market EST, actual revenue USD 1.069 B (forecast USD 979.01 M), actual EPS USD 4.43 (forecast USD 1.828)

Mizuho Securities Maintains Buy Rating on Axsome Therapeutics

BioPharma Credit PLC Announces Financing Allocation for Esperion Transaction

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Lakeside Holding Ltd reported Q3 2026 revenue of $1.33M, a 167% increase from $497K YoY, and net income of $142K, reversing a $1.071M loss from the previous year. Pharmaceutical sales surged 614% year-to-date, with active customers rising from 8 to 14. Infusion products accounted for 93% of sales, though gross margin declined. The company reclassified ABL Chicago as discontinued operations to focus on pharmaceutical distribution.

TradingView

Lakeside

VanEck Pharmaceutical ETF

iShares US Pharma

Invesco Pharmaceuticals ETF

Lakeside Holding Ltd 3Q 2026: Revenue $1.33M, Net income $142K — 10-Q Summary

WGRX

Wellgistics Health, Inc. reported Q1 2026 revenue of $1.56M, down 85.6% from $10.86M a year ago, with a net loss of $7.74M, an improvement from a $32.43M loss in the previous year. The decline in revenue was attributed to reduced distribution activity and liquidity issues, while pharmacy retail sales increased. The company completed acquisitions to enhance its healthcare ecosystem and is investing in sales and marketing to boost brand awareness and customer acquisition.

Wellgistics Health

Wellgistics Health, Inc. 1Q 2026: Revenue $1.56M, EPS ($0.07) — 10-Q Summary

Wellgistics Health reported a significant increase in monthly revenue for its pharmacy segment, rising from $0.1 million in November 2025 to $0.6 million in April 2026. The company is focusing on expanding its direct-to-patient initiatives and integrating new technologies. It has terminated previous non-binding agreements and is in discussions to enhance its PharmacyChain™ capabilities. The first quarter of 2026 saw a net operating loss of $7.742 million, a decrease from the previous year, attributed to cost-cutting measures.

StockTitan

Datavault AI

Wellgistics Health Reports First Quarter 2026 Financials and Provides Business Update | WGRX Stock News

Wellgistics Health Inc. will release its Q1 2026 earnings on May 19, 2026, after market close. The update will provide insights into the performance of its AI-driven pharmacy platform and blockchain distribution model, which connects over 6,500 pharmacies with 200 manufacturers. This earnings report is anticipated to influence investor perceptions regarding the company's competitive position and growth potential in the healthcare sector.

Tip Ranks

Wellgistics Health Schedules First-Quarter 2026 Earnings Release

Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 | WVE Stock News

Wave Life Sciences

SPDR S&P Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

VG Health

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Bioshares Biotech Clinical Trials Fd

VanEck Biotech ETF

iShares Global Healthcare

Ark Genomic Revolution ETF

Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 | WVE Stock News

Cardinal Health Inc. (CAH) shares rose 2.34% to $199.77 on a mixed trading day, marking its fifth consecutive gain. The stock remains 14.48% below its 52-week high of $233.60. Competitors had varied performances, with Amazon up 0.27%, UnitedHealth down 0.69%, and CVS up 0.10%. Trading volume reached 2.4 million, surpassing the 50-day average of 2.0 million.

MarketWatch Automated

Cardinal Health

SPDR S&P Health Equip

iShares US Medical Devices

Dow Jones Industrial Average

S&P 500

Amazon

Unitedhealth

CVS Health

Cardinal Health Inc. Stock Outperforms Competitors On Strong Trading Day

Wave Life Sciences announced positive results from the RestorAATion-2 trial for WVE-006, showing its potential to treat alpha-1 antitrypsin deficiency (AATD) by generating healthy M-AAT and reducing harmful Z-AAT. The therapy demonstrated sustained effects and safety, with FDA feedback expected by mid-2026. WVE-006 offers advantages over existing treatments, including infrequent dosing and reduced risk of liver inflammation. The trial continues to show promise for addressing both lung and liver manifestations of AATD.

Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing | WVE Stock News

McKesson (MCK) reported strong Q4 and full year earnings, with increased sales and net income, leading to a 1.79% rise in stock price to $760.57. Despite recent declines, long-term returns remain robust. Analysts suggest the stock is undervalued at $951.73, driven by earnings power and acquisitions. However, a DCF model indicates potential downside risk, emphasizing the need to weigh earnings against cash generation. Investors are encouraged to explore other opportunities in healthcare.

Simplywall

McKesson

Assessing McKesson (MCK) Valuation After Strong Q4 And Full Year Earnings Results

Cencora's fiscal Q2 2026 results revealed higher sales of $78.36 billion and net income of $1.64 billion, but a revenue miss and lowered growth outlook have raised concerns about its margin expansion narrative. The company confirmed a 4% to 6% revenue growth guidance for 2026, but ongoing investigations and pricing pressures could impact margins. Analysts are cautious, with some projecting only 4.5% annual growth. Cencora's future performance will be critical in restoring investor confidence and shaping its stock sentiment.

Cencora

Will Cencora’s (COR) Revenue Miss and Probes Change Its Margin-Expansion Narrative?

Pomerantz Law Firm is investigating claims for investors of Cencora, Inc. (NYSE: COR) regarding potential securities fraud by the company and its officers. Following Cencora's Q2 2026 results, which missed revenue estimates and lowered growth guidance, the stock price dropped 17.4%. Investors are encouraged to contact Pomerantz for more information.

prnewswire

22:25 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

SPDR Pharmac(XPH.US)

Lakeside Holding Ltd 3Q 2026: Revenue $1.33M, Net income $142K — 10-Q Summary

Wellgistics Health, Inc. 1Q 2026: Revenue $1.56M, EPS ($0.07) — 10-Q Summary

Wellgistics Health Reports First Quarter 2026 Financials and Provides Business Update | WGRX Stock News

Wellgistics Health Schedules First-Quarter 2026 Earnings Release

Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 | WVE Stock News

Cardinal Health Inc. Stock Outperforms Competitors On Strong Trading Day

Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing | WVE Stock News

Assessing McKesson (MCK) Valuation After Strong Q4 And Full Year Earnings Results

Will Cencora’s (COR) Revenue Miss and Probes Change Its Margin-Expansion Narrative?

22:25 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR